| Document |
Document Title |
|
JP2005041879A |
To provide a sodium-hydrogen exchanger type 1 (NHE-1) inhibitor, and a method for using such NHE-1 inhibitor and provide such NHE-1 inhibitor.The invention relates to a compound represented by formula I or pharmaceutically acceptable sal...
|
|
JP2005504730A |
The present invention provides compounds of formula I or pharmaceutically acceptable derivatives thereof: where X is oxygen or sulfur; Y is -S-, -O- or -NR.1-And R2, R3And R4Is as described herein. These compounds are inhibitors of prote...
|
|
JP2005504514A |
Nucleic acid sequences encoding G-coupled protein receptor-related polypeptides are disclosed herein. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide...
|
|
JP2005504766A |
The present invention discloses a method for the modulation of the enzymatic activity of prolyl endopeptidase in various human tissues and their biological effect on intracellular inositol (1,4,5) triphosphate concentration. The present ...
|
|
JP3620055B2 |
|
|
JP2005504009A |
This invention is directed to methods of providing cardioprotection in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, or a p...
|
|
JP2005503106A |
The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides meth...
|
|
JP2005503127A |
The present invention relates to new polynucleotides deriving from the nucleotide sequence of the EPO gene and comprising new SNPs, new polypeptides derived from the natural EPO protein and comprising at least one mutation caused by the ...
|
|
JP2005502621A |
The present invention provides a composition for topical administration comprising an interleukin 2 inhibitor and an antimicrobial agent as active ingredients thereof, wherein said interleukin 2 inhibitor contains a tricyclo compound as ...
|
|
JP2005502632A |
This invention is directed to sulfonyl aromatic hydroxamic acid compounds and salts thereof that, inter alia, inhibit matrix metalloprotease (MMP) activity and/or aggrecanase activity. In some particularly preferred embodiments, the comp...
|
|
JPWO2003030905A1 |
Formula (I): (in the formula, R1 and R4 are independently alkyl or alkoxy; R2 and R3 are independently hydrogen or alkyl; R5 is hydrogen or halogen; R6 is hydrogen or hydroxy; and X1 and X2. Have independently found that the compounds re...
|
|
JP2005501850A |
A method of treating, preventing, or inhibiting pain, inflammation or inflammation-associated disorder in a subject in need of such treatment or prevention provides for treating the subject with chondroitin sulfate and a cyclooxygenase-2...
|
|
JP2004537498A5 |
|
|
JP2004536789A |
The present invention relates to compounds of formula (IA): the preparation thereof, pharmaceutical formulations thereof, and their use in medicine as allosteric adenosine receptor modulators for uses including protection against hypoxia...
|
|
JP2004536876A |
The present invention relates to a pharmaceutical composition comprising as an effective ingredient an oligopeptide identical or analogous to the C-terminal portion of OGP, having stimulatory activity on the production of hematopoietic c...
|
|
JP2004536056A |
Provided herein are methods of treating various medical conditions that require the formation of new bone by administering an effective amount of a RANK antagonist. Antagonists suitable for use in the subject methods include soluble RANK...
|
|
JP2004535364A |
Methods of establishing hematopoietic chimerism useful to correct hematological diseases and promote acceptance of organ transplants include administering busulfan, costimulation blockade, and readily attainable numbers of T-cell deplete...
|
|
JP2004535461A |
The present invention is based on the unexpected discovery that activated protein C (APC) is inactivated by copper. Accordingly, the invention provides improved methods of treating diseases and conditions treatable with APC which utilize...
|
|
JP2004534503A5 |
|
|
JP2004534001A |
The present invention concerns a method for selectively targeting a medicinally-useful agent into cells in which a phospholipid scramblase (PLS) transport system is activated. The method comprises administering the agent, being a PLS-dep...
|
|
JP2004533402A |
Compounds of a general structural formula (I) and salts and solvates thereof, and use of the compounds as PDES inhibitor.
|
|
JP2004532244A |
Metal carbonyls are used to deliver CO having biological activity, for example vasodilation and inhibition of transplant rejection. The metal of the carbonyl is typically of groups 7 to 10, e.g. Fe and Ru. The carbonyl preferably has one...
|
|
JP2004532251A |
Metallotetrapyrrolic compounds having photherapeutic properties useful in photodetection and phototherapy of target issues, particularly porphyrins and azaporphyrins that including gallium in the central pyrrolic core. Also disclosed are...
|
|
JP2004530635A |
An antioxidant compound is disclosed, along with pharmaceutical compositions and methods of treatment which utilize said compound. The compound is characterized by a peptide including at least three amino acid residues of which at least ...
|
|
JP2004529621A |
An isolated multipotent adult stem cell (MASC), which has the capacity to be induced to differentiate to form at least one differentiated cell type of mesodermal, ectodermal or endodermal origin, is new. Independent claims are also inclu...
|
|
JP3572103B2 |
|
|
JP2004529088A |
The present invention describes methods of preventing and treating inflammatory and immune-related diseases or disorders using inhibitors of I kappa B kinase (IKK). Also described are IKK inhibitors effective for the prevention and treat...
|
|
JP2004256463A |
To provide a medicine useful for preventing, ameliorating and treating autoimmune diseases caused by cell adhesion of polymorphonuclear leukocytes, an inflammatory reaction after implantation of a medical device, or the like, without cau...
|
|
JP2004528349A |
The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof wherein the variables are as defined in the description, processes for their preparation,...
|
|
JP2004527479A |
A bisphosphonate for the treatment of osteonecrosis and/or osteonecrosis dissecans. The drug may further he used to prevent the onset of osteonecrosis and/or osetonecrosis dissecans and any complications associated with both diseases.
|
|
JP2004524821A |
The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium.
|
|
JP2004524364A |
Compounds of formula (I): (I), and their salts, solvates, prodrugs, etc., wherein the substituents have the values mentioned herein, are Procollagen C-Proteinase (PCP) inhibitors and have utility in conditions mediated by PCP.
|
|
JP2004524264A |
The invention relates to novel biphenyl derivatives of the general formula (I), wherein R<4 >represents an aromatic heterocycle, and to the physiologically acceptable salts or solvates thereof. The inventive compounds are integrin inhibi...
|
|
JP3553883B2 |
The invention relates to the use of certain fumaric acid monoalkyl esters as salts or a free acid either alone or in combination with a dialkyl fumarate for producing pharmaceutical preparations for use in transplantation medicine, espec...
|
|
JP2004522409A |
The invention provides human kinases (PKIN) and poynucleotides which identify and encode PKIN. The ivention also provides expression vectors, host cels, antibodies, agonists, and antagonists. The invetion also provides methods for diagno...
|
|
JP2004210798A |
To provide a new delivery system of bioerodible drug for the eye, preventing or decreasing newborn blood vessel formation in the eye easily affected to form the newborn blood vessel, such as the eye soon after transplantation.The bioerod...
|
|
JP2004521637A |
The invention provides human kinases and phosphatases (KPP) and polynucleotides which identify and encode KPP. The invention also provides expression vector, host cells, antibodies, agonists, and antagonists. The invention also provides ...
|
|
JP3545789B2 |
PURPOSE: To obtain intraperitoneal adhesion inhibitor which contains carrageenin as an active ingredient and can prevent intestines from adhering to each other or occluding to keep postoperative patients well. CONSTITUTION: The adhesion ...
|
|
JP3545790B2 |
PURPOSE: To obtain intraperitoneal adhesion inhibitor which contains xanthane gum as an active ingredient and can prevent intestines from adhering to each other or occluding to keep postoperative patients well. CONSTITUTION: The adhesion...
|
|
JP2004194665A |
To provide new native variants of a vascular endothelial cell growth factor (VEGF) that binds to heparin with reduced clearance rate compared to native VEGF, and to provide nucleic acid molecules for encoding the variants.The variants of...
|
|
JP2004521074A |
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject...
|
|
JP2004521115A |
The present invention relates to a solid composition useful for tissue gluing, tissue sealing and haemostasis consisting essentially of a) a carrier which has at least one of the following physical properties: elasticity module in the ra...
|
|
JP2004187932A |
To provide an aneurysm obturator which efficiently obturates aneurysm subcutaneously or through a tube with all aneurysms including one in a subarachnoidal blood vessel in a range which a microcatheter reaches as an object for treatment,...
|
|
JP2004189632A |
To provide a method for producing a photosensitive coloring matter carrier, by which various photosensitive coloring matters are supported on the surface of the carrier stably in a high yield and cleaning is readily carried out even with...
|
|
JP2004189753A |
To provide a pharmaceutical formulation containing cyclosporin or macrolide, having improved bioavailability.The pharmaceutical formulation in the form of an emulsion or microemulsion comprises the cyclosporin or the macrolide and a carr...
|
|
JP2004519206A |
The invention provides human protein modification and maintenance molecules (PMMM) and polynucleotides which identify and encode PMMM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The...
|
|
JP2004518649A |
Posterior capsular opacification is inhibited by administration of polymer, having immobilised on the surface, a ligand for a death receptor, preferably joined by a spacer into the lens capsule following cataract surgery. The ligand is p...
|
|
JP2004517108A |
A preparation for douches and/or irrigations of natural or pathological cavities in the human body which comprises water added with at least one gaseous substance selected from carbon dioxide, oxygen, nitrogen, gaseous anaesthetic substa...
|
|
JP2004517069A |
Pyridyl substituted triazoles of formula (I) wherein R1 is naphthyl or phenyl optionally substituted with one or more substituents selected from the group consisting of halo, -O-C1-6alkyl, -S-C1-6alkyl, C1-6alkyl, C1-6haloalkyl, -O-(CH2)...
|
|
JP2004517119A |
Tertiary perfluorocycloamines (TPFCAs)of general formula (1) where n = 1 or 2, m = 2 or 3, X is or wherein at n = 2 X is as the basis for gas transport emulsions. TPFCAs comprise a group of compounds which are close in their physicoc...
|
